{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:05:45Z","timestamp":1793747145535,"version":"4.6.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004809","name":"Financiadora de Estudos e Projetos","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.neuropharm.2014.05.043","type":"journal-article","created":{"date-parts":[[2014,6,11]],"date-time":"2014-06-11T12:28:42Z","timestamp":1402489722000},"page":"57-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"special_numbering":"C","title":["Effects of D-series resolvins on behavioral and neurochemical changes in a fibromyalgia-like model in mice"],"prefix":"10.1016","volume":"86","author":[{"given":"Caroline P.","family":"Klein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalia D.M.","family":"Sperotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izaque S.","family":"Maciel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E.","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra H.","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria M.","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2014.05.043_bib1","doi-asserted-by":"crossref","first-page":"e75543","DOI":"10.1371\/journal.pone.0075543","article-title":"Spinal actions of lipoxin A4 and 17(R)-resolvin D1 attenuate inflammation-induced mechanical hypersensitivity and spinal TNF release","volume":"8","author":"Abdelmoaty","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.neuropharm.2014.05.043_bib2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10194-012-0477-y","article-title":"Characteristics of referred muscle pain to the head from active trigger points in women with myofascial temporomandibular pain and fibromyalgia syndrome","volume":"13","author":"Alonso-Blanco","year":"2012","journal-title":"J.\u00a0Headache Pain"},{"key":"10.1016\/j.neuropharm.2014.05.043_bib3","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jad.2013.08.032","article-title":"Possible involvement of oxido-nitrosative stress induced neuro-inflammatory cascade and monoaminergic pathway: underpinning the correlation between nociceptive and depressive behaviour in a rodent model","volume":"151","author":"Arora","year":"2013","journal-title":"J.\u00a0Affect. Disord."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib4","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1476-5381.2011.01568.x","article-title":"17(R)-resolvin D1 specifically inhibits transient receptor potential ion channel vanilloid 3 leading to peripheral antinociception","volume":"165","author":"Bang","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2147\/JPR.S43395","article-title":"Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study","volume":"6","author":"Bateman","year":"2013","journal-title":"J.\u00a0Pain Res."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib6","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.4049\/jimmunol.1101305","article-title":"Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice","volume":"187","author":"Bento","year":"2011","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib7","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.2174\/138920111798357258","article-title":"Fibromyalgia: mechanisms, current treatment and animal models","volume":"12","author":"Brederson","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2046-4053-2-18","article-title":"Systematic review and network meta-analysis of interventions for fibromyalgia: a protocol","volume":"2","author":"Busse","year":"2013","journal-title":"Syst. Rev."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/rheumatology\/kem345","article-title":"A\u00a0subset of fibromyalgia patients have findings suggestive of chronic inflammatory demyelinating polyneuropathy and appear to respond to IVIg","volume":"47","author":"Caro","year":"2008","journal-title":"Rheumatol. Oxf."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/art.38662","article-title":"Evidence of abnormal epidermal nerve fiber density in fibromyalgia: clinical and immunologic implications","author":"Caro","year":"2014","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib11","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/1745017901309010120","article-title":"The use of antidepressants in the long-term treatment should not improve the impact of fibromyalgia on quality of life","volume":"9","author":"Carta","year":"2013","journal-title":"Clin. Pract. Epidemiol. Ment. Health"},{"key":"10.1016\/j.neuropharm.2014.05.043_bib12","doi-asserted-by":"crossref","first-page":"585419","DOI":"10.1155\/2012\/585419","article-title":"Neurobiology underlying fibromyalgia symptoms","volume":"2012","author":"Ceko","year":"2012","journal-title":"Pain Res. Treatment"},{"key":"10.1016\/j.neuropharm.2014.05.043_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","article-title":"Quantitative assessment of tactile allodynia in the rat paw","volume":"53","author":"Chaplan","year":"1994","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2014.05.043_bib14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10571-012-9871-x","article-title":"An evaluation of the antinociceptive effects of Phalpha1beta, a neurotoxin from the spider Phoneutria nigriventer, and omega-conotoxin MVIIA, a cone snail Conus magus toxin, in rat model of inflammatory and neuropathic pain","volume":"33","author":"de Souza","year":"2013","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.toxicon.2014.01.015","article-title":"The effects of Ph\u03b11\u03b2, a spider toxin, calcium channel blocker, in a mouse fibromyalgia model","volume":"81C","author":"de Souza","year":"2014","journal-title":"Toxicon"},{"key":"10.1016\/j.neuropharm.2014.05.043_bib16","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/ar4402","article-title":"Animal models of fibromyalgia","volume":"15","author":"Desantana","year":"2013","journal-title":"Arthritis Res. Therapy"},{"key":"10.1016\/j.neuropharm.2014.05.043_bib17","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev.pa.20.040180.002301","article-title":"Efficient analysis of experimental observations","volume":"20","author":"Dixon","year":"1980","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib18","doi-asserted-by":"crossref","first-page":"G1085","DOI":"10.1152\/ajpgi.00542.2011","article-title":"Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome","volume":"302","author":"Feng","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jneumeth.2011.03.023","article-title":"Development and validation of an ultra-high performance liquid chromatography-tandem mass-spectrometry (UHPLC-MS\/MS) method for the simultaneous determination of neurotransmitters in rat brain samples","volume":"198","author":"Gonzalez","year":"2011","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2014.05.043_bib20","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/art.10225","article-title":"Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia","volume":"46","author":"Gracely","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/ar3136","article-title":"Elevated excitatory neurotransmitter levels in the fibromyalgia brain","volume":"12","author":"Harris","year":"2010","journal-title":"Arthritis Res. Therapy"},{"key":"10.1016\/j.neuropharm.2014.05.043_bib22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.pain.2010.11.021","article-title":"Enduring prevention and transient reduction of postoperative pain by intrathecal resolvin D1","volume":"152","author":"Huang","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2014.05.043_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0166-4328(86)90088-4","article-title":"A\u00a0modified hot-plate test sensitive to mild analgesics","volume":"21","author":"Hunskaar","year":"1986","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1744-8069-8-32","article-title":"Patients with fibromyalgia display less functional connectivity in the brain's pain inhibitory network","volume":"8","author":"Jensen","year":"2012","journal-title":"Mol. Pain"},{"key":"10.1016\/j.neuropharm.2014.05.043_bib25","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.tins.2011.08.005","article-title":"Emerging roles of resolvins in the resolution of inflammation and pain","volume":"34","author":"Ji","year":"2011","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib26","first-page":"1765","article-title":"Pure docosahexaenoic acid can improve depression behaviors and affect HPA axis in mice","volume":"16","author":"Jiang","year":"2012","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jneuroim.2011.10.013","article-title":"Evidence of central inflammation in fibromyalgia-increased cerebrospinal fluid interleukin-8 levels","volume":"242","author":"Kadetoff","year":"2012","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib28","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/gps.3800","article-title":"Pregabalin augmentation of antidepressants in older patients with comorbid depression and generalized anxiety disorder-an open-label study","volume":"28","author":"Karaiskos","year":"2013","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.05.043_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/acr.22071","article-title":"Clinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin or pregabalin","author":"Kim","year":"2013","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib30","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0031-6997(24)01514-X","article-title":"Animal models of nociception","volume":"53","author":"Le Bars","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib31","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1476-5381.2011.01345.x","article-title":"The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvant-induced arthritis in rats","volume":"164","author":"Lima-Garcia","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib32","doi-asserted-by":"crossref","first-page":"e77227","DOI":"10.1371\/journal.pone.0077227","article-title":"Synergistic effects of celecoxib and bupropion in a model of chronic inflammation-related depression in mice","volume":"8","author":"Maciel","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.neuropharm.2014.05.043_bib33","first-page":"S86","article-title":"Focus on pain mechanisms and pharmacotherapy in the treatment of fibromyalgia syndrome","volume":"27","author":"Malemud","year":"2009","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib34","article-title":"Including a range of outcome targets offers a broader view of fibromyalgia treatment outcome: results from a retrospective review of multidisciplinary treatment","author":"Marcus","year":"2013","journal-title":"Musculoskelet. Care"},{"key":"10.1016\/j.neuropharm.2014.05.043_bib35","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.berh.2011.01.015","article-title":"Pharmacotherapy of fibromyalgia","volume":"25","author":"Mease","year":"2011","journal-title":"Best Pract. Research. Clin. Rheumatol."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pain.2009.05.024","article-title":"Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: a putative animal model of fibromyalgia","volume":"146","author":"Nagakura","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2014.05.043_bib37","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.bbr.2011.09.023","article-title":"Different pathophysiology underlying animal models of fibromyalgia and neuropathic pain: comparison of reserpine-induced myalgia and chronic constriction injury rats","volume":"226","author":"Nagakura","year":"2012","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib38","first-page":"1358","article-title":"Interstitial cystitis\/painful bladder syndrome and associated medical conditions with an emphasis on irritable bowel syndrome, fibromyalgia and chronic fatigue syndrome","volume":"184","author":"Nickel","year":"2010","journal-title":"J.\u00a0Urol."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib39","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pbb.2013.04.007","article-title":"Systemic administration of 5-HT(2C) receptor agonists attenuates muscular hyperalgesia in reserpine-induced myalgia model","volume":"108","author":"Ogino","year":"2013","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib40","doi-asserted-by":"crossref","first-page":"18433","DOI":"10.1523\/JNEUROSCI.4192-11.2011","article-title":"Resolvin D2 is a potent endogenous inhibitor for transient receptor potential subtype V1\/A1, inflammatory pain, and spinal cord synaptic plasticity in mice: distinct roles of resolvin D1, D2, and E1","volume":"31","author":"Park","year":"2011","journal-title":"J.\u00a0Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jnr.22512","article-title":"Central amplification and fibromyalgia: disorder of pain processing","volume":"89","author":"Petersel","year":"2011","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib42","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1471-230X-12-148","article-title":"Resolvin D1 reverses chronic pancreatitis-induced mechanical allodynia, phosphorylation of NMDA receptors, and cytokines expression in the thoracic spinal dorsal horn","volume":"12","author":"Quan-Xin","year":"2012","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib43","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1523\/JNEUROSCI.4389-07.2008","article-title":"Neuropathic pain-like behavior after brachial plexus avulsion in mice: the relevance of kinin B1 and B2 receptors","volume":"28","author":"Quintao","year":"2008","journal-title":"J.\u00a0Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib44","article-title":"A\u00a0review of the effects of pregabalin on sleep disturbance across multiple clinical conditions","author":"Roth","year":"2013","journal-title":"Sleep. Med. Rev."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib45","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nrrheum.2011.98","article-title":"Fibromyalgia: from pathophysiology to therapy","volume":"7","author":"Schmidt-Wilcke","year":"2011","journal-title":"Nat. Reviews. Rheumatol."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib46","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.coph.2013.05.012","article-title":"Resolution phase lipid mediators of inflammation: agonists of resolution","volume":"13","author":"Serhan","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib47","first-page":"93","article-title":"TRP-channels as key integrators of lipid pathways in nociceptive neurons","volume":"53C","author":"Sisignano","year":"2013","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib48","doi-asserted-by":"crossref","first-page":"E217","DOI":"10.36076\/ppj.2011\/14\/E217","article-title":"Fibromyalgia: an afferent processing disorder leading to a complex pain generalized syndrome","volume":"14","author":"Smith","year":"2011","journal-title":"Pain Physician"},{"key":"10.1016\/j.neuropharm.2014.05.043_bib49","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1517\/14656566.2012.687373","article-title":"Pregabalin for the treatment of fibromyalgia","volume":"13","author":"Smith","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib50","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nm0510-518","article-title":"Fighting off pain with resolvins","volume":"16","author":"Sommer","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib51","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11926-012-0277-z","article-title":"Peripheral and central mechanisms of fatigue in inflammatory and noninflammatory rheumatic diseases","volume":"14","author":"Staud","year":"2012","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib52","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/1471-2474-12-245","article-title":"Systematic review with meta-analysis: cytokines in fibromyalgia syndrome","volume":"12","author":"\u00dc\u00e7eyler","year":"2011","journal-title":"BMC Musculoskelet. Disorders"},{"key":"10.1016\/j.neuropharm.2014.05.043_bib53","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1002\/art.22026","article-title":"Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain","volume":"54","author":"\u00dc\u00e7eyler","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib54","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1093\/brain\/awt053","article-title":"Small fibre pathology in patients with fibromyalgia syndrome","volume":"136","author":"\u00dc\u00e7eyler","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2014.05.043_bib55","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1124\/mol.112.077636","article-title":"alpha2delta ligands act as positive modulators of adult hippocampal neurogenesis and prevent depression-like behavior induced by chronic restraint stress","volume":"82","author":"Valente","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib56","first-page":"218733","article-title":"Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers","author":"Veselinovi\u0107","year":"2011","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib57","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/0269881112466183","article-title":"Effects of antipsychotic treatment on cognition in healthy subjects","volume":"27","author":"Veselinovi\u0107","year":"2013","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib58","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1053\/eujp.2002.0329","article-title":"Gabapentin and pregabalin suppress tactile allodynia and potentiate spinal cord stimulation in a model of neuropathy","volume":"6","author":"Wallin","year":"2002","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.neuropharm.2014.05.043_bib59","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/acr.20140","article-title":"The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity","volume":"62","author":"Wolfe","year":"2010","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib60","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/cns.12069","article-title":"Resolvin D1, an endogenous lipid mediator for inactivation of inflammation-related signaling pathways in microglial cells, prevents lipopolysaccharide-induced inflammatory responses","volume":"19","author":"Xu","year":"2013","journal-title":"CNS Neurosci. Therap."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib61","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11011-013-9404-4","article-title":"Ferulic acid increases pain threshold and ameliorates depression-like behaviors in reserpine-treated mice: behavioral and neurobiological analyses","volume":"28","author":"Xu","year":"2013","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.neuropharm.2014.05.043_bib62","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nm.2123","article-title":"Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions","volume":"16","author":"Xu","year":"2010","journal-title":"Nat. Med."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814002196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814002196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:56:18Z","timestamp":1762214178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390814002196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":62,"alternative-id":["S0028390814002196"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.05.043","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of D-series resolvins on behavioral and neurochemical changes in a fibromyalgia-like model in mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.05.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}